4300 Hacienda Drive
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
Roche is the world leader in molecular and tissue diagnostics, and one of the leaders in clinical sequencing. As the innovation engine for Roche Diagnostics,Roche Molecular Solutions is translating cutting-edge science and innovation into clinical practice.
Visit our Career Blogs to see what our employees have to say about their life at Roche!
165 articles with Roche
Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
Transaction valued at up to $760 million, including $75 million upfront payment, plus royalties up to 20%
Memorial Sloan Kettering's Chief Executive Officer Craig Thompson has resigned from the boards of directors at Merck and Charles River Labs as the cancer center continues to be scrutinized for its ties to the pharmaceutical industry.
Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members
Virion Therapeutics, LLC today announced the appointment of its inaugural Board of Directors and Scientific Advisory Board.
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
Dabbagh Poised to Lead Second Genome's Next Phase of Growth Focused on Therapeutic Drug Discovery and Development Derived from Microbiome Science.
Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
Centrexion Therapeutics Corporation today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company.
The Economist Intelligence Unit (EIU) has carried out two complementary studies on lung cancer in Latin America: an analysis of the economic costs and an assessment of the policy response (the Latin America Lung Cancer Traffic Lights).
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
This is a co-formulation with Halozyme's proprietary recombinant human hyaluronidase enzyme.
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
GT Biopharma Inc. is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms.
There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals’ Onpattro, got approved on August 10. That makes 2018 a landmark year. But another year—2014—may prove just as influential for the field and how it develops.
Shares of AbbVie are inching up this morning after the company announced it had secured regulatory approval for Imbruvica as a treatment for patients with a rare blood disease.
Roche receives FDA approval for cobas EGFR Mutation Test v2 as companion diagnostic with IRESSA (gefitinib) in first-line treatment of patients with non-small cell lung cancer (NSCLC)
New indication approval for cobas EGFR Mutation Test v2 as companion diagnostic, follows previous approvals with Tarceva (erlotinib) and TAGRISSO (osimertinib)
As Brexit creeps closer and closer, the British government, as well as pharmaceutical companies and the European Medicines Agency, are preparing contingency plans for dealing with the possibility that healthcare-related companies will not have contracts in place in time.
NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.
Roche to showcase how labs are driving change across health networks to address PAMA and other challenges at AACC 2018 Clinical Lab Expo
Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care
7/31/2018Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
For the first time, Merck’s Keytruda beat out Bristol-Myers Squibb’s Opdivo in sales.
Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of the year and a 20 percent increase in its core earnings per share (EPS).